Mark F. Kubik
Corporate Officer/Principal chez GENOR BIOPHARMA HOLDINGS LIMITED
Profil
Mark F.
Kubik is currently the Chief Business Officer at Genor Biopharma Holdings Ltd.
He previously worked as the Head of Business Development at Merck & Co., Inc., and as the Chief Business Officer at Actinium Pharmaceuticals, Inc. and OncoImmune, Inc. Kubik received his undergraduate degree from the University of Colorado Boulder and his MBA from The Leeds School of Business.
Postes actifs de Mark F. Kubik
| Sociétés | Poste | Début |
|---|---|---|
| GENOR BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 17/08/2021 |
Anciens postes connus de Mark F. Kubik
| Sociétés | Poste | Fin |
|---|---|---|
OncoImmune, Inc.
 OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Corporate Officer/Principal | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Mark F. Kubik
| University of Colorado Boulder | Undergraduate Degree |
| The Leeds School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
| GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
OncoImmune, Inc.
OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Health Technology |